Want to see KEQU full AI Analyst Report?
Top Page
Kewaunee Scientific
(NASDAQ:KEQU)
Select Model
Select Model
Rating:56Neutral
Price Target:
$35.00
â–¼(-7.36% Downside)
Action:Reiterated
Date:09/12/26
The score is held back primarily by mixed fundamentals (margin compression, negative TTM revenue growth, higher leverage, and weaker free cash flow) and bearish technicals (price below key moving averages with negative MACD). A reasonable P/E multiple and supportive—but not transformative—corporate updates partially offset these risks.
Positive Factors
Multi-year growth and scale
The substantial multi-year increase in revenue and EBITDA indicates that Kewaunee has expanded its operating scale and market reach. A larger platform can improve customer access, support investment in capabilities, and provide a stronger base for sustained growth than a single project-driven gain.
Negative Factors
Revenue slowdown
The shift from prior growth to negative TTM revenue growth signals that demand or project conversion has weakened. Lower volume can reduce operating leverage and make earnings more dependent on individual project timing, limiting the durability of recent expansion over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year growth and scale
The substantial multi-year increase in revenue and EBITDA indicates that Kewaunee has expanded its operating scale and market reach. A larger platform can improve customer access, support investment in capabilities, and provide a stronger base for sustained growth than a single project-driven gain.
Read all positive factors
Kewaunee Scientific Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyKewaunee Scientific (KEQU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$98.82M
Dividend Yield4.89%
Average Volume (3M)2.75K
Price to Earnings (P/E)12.0
Beta (1Y)0.92
Revenue Growth5.33%
EPS Growth-33.32%
CountryUS
Employees1,231
SectorConsumer Cyclical
Sector Strength84
IndustryFurnishings, Fixtures & Appliances
Share Statistics
EPS (TTM)2.86
Shares Outstanding2,868,511
10 Day Avg. Volume2,255
30 Day Avg. Volume2,751
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.42
Price to Sales (P/S)0.38
P/FCF Ratio7.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kewaunee Scientific Business Overview & Revenue Model
Company Description
Kewaunee Scientific Corporation, established in 1906 and based in Statesville, North Carolina, specializes in providing custom furniture and infrastructure systems for scientific, medical, and technical settings. The company manages its operations...
How the Company Makes Money
Kewaunee Scientific primarily makes money by selling laboratory furniture and ventilation-related lab products, along with associated project and installation services, to customers building new labs or renovating existing facilities. Revenue is g...
Kewaunee Scientific Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
58
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.21M | 282.00M | 240.47M | 203.75M | 219.49M | 168.87M |
| Gross Profit | 79.15M | 80.44M | 68.86M | 52.05M | 35.59M | 24.22M |
| EBITDA | 22.10M | 23.88M | 22.76M | 18.04M | 8.16M | 916.00K |
| Net Income | 8.23M | 9.62M | 11.40M | 18.75M | 1.36M | -6.00M |
Balance Sheet | ||||||
| Total Assets | 175.80M | 178.31M | 194.65M | 134.77M | 118.90M | 118.77M |
| Cash, Cash Equivalents and Short-Term Investments | 8.25M | 11.62M | 14.94M | 23.27M | 8.08M | 4.43M |
| Total Debt | 55.47M | 30.18M | 50.16M | 11.00M | 12.92M | 67.56M |
| Total Liabilities | 98.58M | 101.50M | 128.41M | 78.56M | 80.41M | 82.59M |
| Stockholders Equity | 75.00M | 74.72M | 64.46M | 54.76M | 37.41M | 35.69M |
Cash Flow | ||||||
| Free Cash Flow | 10.88M | 14.70M | 12.62M | 15.19M | -7.94M | -9.79M |
| Operating Cash Flow | 14.82M | 18.63M | 14.78M | 19.56M | -3.79M | -7.88M |
| Investing Cash Flow | -3.94M | -3.94M | -30.90M | -4.37M | -4.15M | -1.91M |
| Financing Cash Flow | -20.36M | -19.33M | 7.41M | -3.01M | 14.93M | 11.03M |
Kewaunee Scientific Technical Analysis
Negative
37.78
Price Trends
36.62
Negative
37.13
Negative
37.61
Negative
Market Momentum
-0.40
Positive
33.75
Neutral
28.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Negative. The current price of 37.78 is above the 20-day moving average (MA) of 36.62, above the 50-day MA of 36.62, and above the 200-day MA of 37.61, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 33.75 is Neutral, neither overbought nor oversold. The STOCH value of 28.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KEQU.
Kewaunee Scientific Risk Analysis
Kewaunee Scientific disclosed 28 risk factors in its most recent earnings report. Kewaunee Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kewaunee Scientific Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $333.07M | 12.24 | 19.78% | 1.04% | 4.10% | 73.26% | |
69 Neutral | $552.69M | 14.06 | 8.40% | 21.93% | -5.72% | -22.50% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
56 Neutral | $98.82M | 12.05 | 11.34% | 4.89% | 5.33% | -33.32% | |
56 Neutral | $153.16M | 27.96 | 3.32% | 4.52% | 1.96% | 122.75% | |
54 Neutral | $97.74M | -40.23 | -2.32% | 1.61% | -18.97% | -118.61% | |
53 Neutral | $137.82M | -7.64 | -10.59% | 4.48% | -28.13% | -38.44% |
* Consumer Cyclical Sector Average
KEQU
Kewaunee Scientific
34.45
-10.85
-23.95%
BSET
Bassett Furniture
17.69
2.16
13.92%
ETD
Ethan Allen
21.93
-1.98
-8.28%
FLXS
Flexsteel
81.40
33.73
70.75%
HOFT
Hooker Furniture
12.83
3.30
34.64%
VIRC
Virco Manufacturing
6.20
-1.70
-21.51%
Kewaunee Scientific Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Kewaunee Scientific Shareholders Endorse Board and Governance
Positive
Aug 27, 2026
On August 26, 2026, Kewaunee Scientific Corporation held its Annual Meeting of Shareholders, where investors re-elected Class I directors Thomas D. Hull III, David S. Rhind, and John D. Russell to three-year terms, signaling continuity in the comp...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Kewaunee Scientific Highlights Strong Fiscal 2026 Growth Strategy
Positive
Aug 26, 2026
Kewaunee Scientific has posted an investor presentation and script for its August 26, 2026 virtual annual shareholder meeting, detailing multi-year growth, segment performance and the strategic integration of its Lab Products Group platform. The c...
Business Operations and StrategyFinancial Disclosures
Kewaunee Scientific to Release Q1 FY2027 Results
Neutral
Aug 25, 2026
On August 25, 2026, Kewaunee Scientific Corporation announced it would release its first quarter fiscal year 2027 financial results on September 9, 2026, after the close of trading.The planned disclosure underscores the company’s ongoing com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.